| Literature DB >> 26904146 |
Mohamed Saeed Zayed Al-Ayed1, Ahmed Morad Asaad2, Mohamed Ansar Qureshi2, Hany Goda Attia3, Abduljabbar Hadi AlMarrani4.
Abstract
Much effort has focused on examining the inhibitory effect of Salvadora persica (miswak) on oral microorganisms, but information concerning its antibacterial activity against other human pathogens, particularly multidrug resistant (MDR) isolates, is scarce. Therefore, this study aimed to assess the in vitro antibacterial activities of Salvadora persica L. extracts against 10 MDR bacterial clinical isolates other than oral pathogens. The antibacterial activity of aqueous and methanol miswak extracts was assessed using the agar dilution and minimum inhibitory concentration (MIC) methods. Overall, the 400 mg/mL of miswak extract was the most effective on all strains. The methanol extract exhibited a stronger antibacterial activity against Gram-negative (3.3-13.6 mm) than Gram-positive (1.8-8.3 mm) bacteria. The lowest MIC value was seen for E. coli (0.39, 1.56 µg/mL), followed by Streptococcus pyogenes (1.56 µg/mL). The highest MIC value (6.25, 12.5 µg/mL) was recorded for methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii, and Stenotrophomonas maltophilia. This study demonstrates, for the first time, the moderate to strong antibacterial activity of miswak extracts against all tested MDR-pathogens. Methanol extract appears to be a potent antimicrobial agent that could be considered as complementary and alternative medicine against resistant pathogens. Further studies on a large number of MDR organisms are necessary to investigate and standardize the inhibitory effect of miswak extracts against these emerging pathogens.Entities:
Year: 2016 PMID: 26904146 PMCID: PMC4745819 DOI: 10.1155/2016/7083964
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The antibacterial activities of aqueous and methanol extracts of miswak against 10 MDR pathogenic organisms.
| MDR bacterial isolates | The diameter of inhibition zones (mm) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Aqueous extract (mg/mL) | Methanol extract (mg/mL) | Positive control | ||||||||
| 400 | 200 | 100 | 50 | 400 | 200 | 100 | 50 | VAN (30 | TOB (10 | |
| MRSA | 6.2 | 5.1 | 3.8 | 3.0 | 8.3 | 5.1 | 3.4 | 2.0 | 18 | NT |
| MRSE | 6.0 | 4.8 | 3.2 | 2.7 | 7.6 | 5.8 | 3.1 | 1.8 | 19 | NT |
|
| 6.4 | 4.5 | 3.5 | 2.6 | 7.4 | 5.4 | 3.0 | 2.2 | 21 | NT |
|
| 6.1 | 5.2 | 4.0 | 3.2 | 7.8 | 6.1 | 5.0 | 2.9 | 19 | NT |
|
| 12.3 | 9.7 | 7.2 | 5.3 | 13.6 | 9.2 | 6.5 | 4.8 | NT | 21 |
|
| 11.8 | 8.5 | 7.0 | 4.3 | 12.7 | 8.7 | 5.8 | 4.6 | NT | 20 |
|
| 10.5 | 8.0 | 5.9 | 4.0 | 10.2 | 8.8 | 6.2 | 4.2 | NT | 17 |
|
| 12.0 | 9.2 | 5.6 | 4.8 | 12.5 | 8.1 | 5.0 | 4.5 | NT | 18 |
|
| 8.5 | 7.3 | 4.6 | 3.2 | 9.8 | 8.0 | 5.2 | 3.5 | NT | 16 |
|
| 8.2 | 7.0 | 4.8 | 3.0 | 9.5 | 7.6 | 4.9 | 3.3 | NT | 16 |
MRSA: methicillin-resistant staphylococcus aureus, MRSE: methicillin-resistant staphylococcus epidermidis.
VAN: vancomycin, TOB: tobramycin, and NT: Not tested.
The CLSI zone diameter interpretive criteria for vancomycin (VAN): ≥15 mm: susceptible, 13-14 mm: intermediate, and ≤12 mm: resistant [21].
The CLSI zone diameter interpretive criteria for tobramycin (TOB): ≥17 mm: susceptible, 15-16 mm: intermediate, and ≤14 mm: resistant [21].
The MIC values of aqueous and methanol extracts of miswak against 10 MDR pathogenic organisms.
| MDR bacterial | MIC values (mg/mL) | MIC values ( | ||
|---|---|---|---|---|
| Miswak extracts | Positive control | |||
| Aqueous | Methanol | VAN | TOB | |
| MRSA | 12.5 | 6.25 | 1.0 | NT |
| MRSE | 6.25 | 3.125 | 0.5 | NT |
|
| 1.56 | 1.56 | 0.125 | NT |
|
| 3.125 | 3.125 | 0.5 | NT |
|
| 1.56 | 0.39 | NT | 0.25 |
|
| 3.125 | 0.781 | NT | 0.5 |
|
| 6.25 | 1.56 | NT | 1.0 |
|
| 1.56 | 1.56 | NT | 2.0 |
|
| 12.5 | 6.25 | NT | 8.0 |
|
| 12.5 | 6.25 | NT | 4.0 |
MRSA: methicillin-resistant staphylococcus aureus, MRSE: methicillin-resistant staphylococcus epidermidis.
VAN: vancomycin, TOB: tobramycin, and NT: not tested.
The CLSI MIC Interpretive Criteria for vancomycin (VAN): ≤2 µg/mL: Susceptible, 4–8 µg/mL: Intermediate, ≥16 µg/mL: Resistant [21].
The CLSI MIC interpretive criteria for tobramycin (TOB): ≤4 ug/mL: susceptible, 8 µg/mL: intermediate, and ≥16 µg/mL: resistant [21].